Significance of Third Trimester Placental Location

Missed the updated IDSA histoplasmosis guideline? This easy-to-read FAQ covers what clinicians caring for pregnant patients need to know.

The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.

In the debut episode of Missed & Dismissed, Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, talks with Charis Chambers, MD, about PCOS, the push to rename it PMOS, and why diagnostic delays so often begin in adolescence.

Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.

Placentas from older mothers held less NAD+, and in aged pregnant mice, nicotinamide riboside or the CD38 inhibitor 78c restored placental NAD+ and improved fetal growth.

Hugh Taylor, MD, outlines a stepwise approach to endometriosis therapy, from first-line oral contraceptives to oral GnRH antagonists for progestin-resistant patients.

Hosted by Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, the monthly series brings clinicians, researchers, innovators, advocates, and other voices across women’s health into conversations that rarely happen in the same room.

A new book from Sameena Rahman, MD, reclaims "brown girls' disease" as a lens for examining how dismissal—of conditions, anatomy, and patients—undermines sexual medicine care for all women.